Increased Biomarker Testing Could Boost Oncology Market In China
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China's oncology market is one of the fastest-growing subsectors with cancer now the second-leading cause of death in China. Although the cost of oncology drugs is often prohibitive, increased biomarker testing could help increase access to innovative cancer treatments in China
You may also be interested in...
Oncology Market In China Outpaces Pharma Industry; Targeted Therapies Enjoy Fastest Growth - Citi Research
SHANGHAI - Although anti-infective drugs still dominate China's pharma market with roughly one-fourth of the total drug sales in hospitals, China's oncology market is outpacing the larger global market
Oncology Market In China Outpaces Pharma Industry; Targeted Therapies Enjoy Fastest Growth - Citi Research
SHANGHAI - Although anti-infective drugs still dominate China's pharma market with roughly one-fourth of the total drug sales in hospitals, China's oncology market is outpacing the larger global market
Oncology Market In China Outpaces Pharma Industry; Targeted Therapies Enjoy Fastest Growth - Citi Research
Three national surveys revealed that lung, liver, stomach and esophageal cancer were the top four killers in the last 30 years, accounting for roughly 70% of deaths from cancer in China.